Atrasentan is an investigational drug. That means it has not yet been approved by the FDA as a medicine. Researchers want to find out if taking atrasentan along with a drug called an SGLT2 inhibitor is safe and helps people with IgA nephropathy.
This study is being done to see if the study drug, called BI 764198, may help people with a type of kidney disease called focal segmental glomerulosclerosis (abbreviated FSGS). Researchers are trying to figure out if the study drug can reduce the amount of protein in your urine, also known as "proteinuria".
Have you been diagnosed with chronic kidney disease and type 2 diabetes? If so, you may qualify for a research study to see if two medicines help to treat kidney disease.
Have you been hospitalized for anti-GBM disease (Goodpasture disease)? You may be able to take part in a research study to help us learn if adding a drug to your treatment could help stop inflammation faster and help protect the kidneys.
People with kidney disease that have the APOL1 risk variant are at a greater risk for developing protein in their urine and chronic kidney disease. This research study is being done to determine if the investigational drug, VX-147 can slow or stop the worsening of kidney function as well as target the underlying cause of kidney disease.
You are participating in a clinical research study to investigate whether voclosporin (the study drug) added to standard treatment is able to reduce Lupus Nephritis disease activity in adolescents. This study involves 24 weeks of treatment and you will be required to follow specific instructions of the study as explained by your study doctor and team
Does your child have frequently relapsing or steroid dependent nephrotic syndrome? This study is testing a medicine called obinutuzumab, and comparing it with another one, mycophenolate mofetil (MMF), to see which works better for children with nephrotic syndrome.
The purpose of the EPPIK study is to gain further experience on the use of sparsentan in children.
We still have a lot to learn about why people develop glomerular disease and what the best medicines are to treat these diseases. Diabetes is a common, chronic illness and many people with glomerular disease also have diabetes. Currently, there is no information telling us the best ways to treat patients with both diabetes and glomerular disease, or how to counsel them about prognosis and risks for complications. This substudy of the Cure Glomerulopathy Network brings together information and laboratory specimens from patients with diabetes and glomerular disease to speed up and improve health research for their care.
The study tests the safety and efficacy of a new type of drug, administered by intravenous infusion, for the treatment of lupus nephritis or IgA Nephropathy. You might be on the drug or on the placebo (no active drug ) and will help to figure out if this new drug is a good alternative or complement to existing drugs.